Rabies vaccine - Chengdu Kanghua Biological Products

Drug Profile

Rabies vaccine - Chengdu Kanghua Biological Products

Alternative Names: Freeze dried rabies vaccine (MRC-5-cell) - Chengdu Kanghua Biological Products; Freeze dried rabies vaccine - Chengdu Kanghua Biological Products; HDCV; HDCV rabies vaccine - Chengdu Kanghua Biological Products; Human diploid cell rabies vaccine - Chengdu Kanghua Biological Products; Lyophilized human diploid cell rabies vaccine (HDCV) - Chengdu Kanghua Biological Products; MRC-5 cell rabies vaccine - Chengdu Kanghua Biological Products

Latest Information Update: 04 May 2016

Price : $50

At a glance

  • Originator Chengdu Kanghua Biological Products
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Rabies

Most Recent Events

  • 07 Mar 2016 Phase-III clinical trials in Rabies (Prevention, In adolescents, In volunteers, In children, In adults) in China (IM) (ChiCTR-PIR-16008129)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top